The US Foods and Drug Administration (Fda)’s approval of Alzheimer’s therapy aducanumab may possibly have been the agency’s most controversial...
Put
In 2019, Biogen introduced that it was abandoning its late stage drug for Alzheimer’s, aducanumab but then in 2021 they...
